ÂÜÀòÂÒÂ×

Ms Diaz joined in October 2021 as Senior Vice President, Regulatory Affairs, bringing more than 18 years of experience in both large and small pharmaceutical companies across key regions.

Prior to joining Verona Pharma, Ms Diaz served at ReViral as Vice President, Regulatory Affairs, where she led global regulatory strategy for the development of sisunatovir for the treatment of respiratory syncytial virus. Previously, Ms Diaz was Vice President, Regulatory and Quality at Dova Pharmaceuticals where she built the regulatory function from the ground up and led regulatory strategy development and implementation efforts for Doptelet® (avatrombopag), resulting in marketing approvals in the US, EU and China – the first marketing approvals for the company.

Ms Diaz has also held various roles in regulatory affairs and regulatory operations at UCB, Chimerix, and GlaxoSmithKline, and has worked across multiple therapeutic areas including hematology, antivirals, and immunology.

Caroline holds a BS in chemistry from Hope College in Holland, Michigan, and an MA in organic chemistry from the University of North Carolina-Chapel Hill.